Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children: a pilot study

Gian Luigi Marseglia, Mariangela Tosca, Ignazio Cirillo, Amelia Licari, Maddalena Leone, Alessia Marseglia, Anna Maria Castellazzi, Giorgio Ciprandi, Gian Luigi Marseglia, Mariangela Tosca, Ignazio Cirillo, Amelia Licari, Maddalena Leone, Alessia Marseglia, Anna Maria Castellazzi, Giorgio Ciprandi

Abstract

Probiotic milk has been previously demonstrated to reduce the number of respiratory infections (RI) among children attending day care centres. Thus, this pilot study was aimed to assess the efficacy and the safety of 3 month treatment with Bacillus clausii in the prevention of recurrent respiratory infections (RRI) in children. Eighty children with RRI were studied: 40 of them were randomly treated with B. clausii for 3 months, and followed up for further 3 months; 40 were included in the control group during the same period. Children treated with B. clausii had shorter duration of RI in comparison with the control group both during the treatment phase (mean 11.7 days vs 14.37; p=0.037) and the follow-up period (mean 6.6 days vs 10.92; p=0.049). This effect was evident also in allergic children during the follow-up. In conclusion, this pilot study provides the first preliminary evidence that B. clausii may exert a significant and persistent impact on RI in children and is safe and well tolerated.

Figures

Figure 1
Figure 1
Duration of RI (expressed as days in treated and nontreated as children with RRI during the treatment period (white column) and the follow-up (grey column). Abbreviations: RI, respiratory infections; RRI, recurrent respiratory infections.
Figure 2
Figure 2
Duration of RI (expressed as days) in treated and nontreated allergic children with RRI during the treatment period (white column) and the follow-up (grey column). Abbreviations: RI, respiratory infections; RRI, recurrent respiratory infections.

References

    1. [BWHO] Bull World Health Organ. Acute respiratory infections: the forgotten pandemic. Bull World Health Organ. 1998;76:101–3.
    1. Ciprandi G, Tosca MA, Milanese M, et al. Cytokines evaluation in nasal lavage of allergic children after bacillus clausii administration: a pilot study. Ped Allergy Immunol. 2004;15:148–51.
    1. Ciprandi G, Vizzaccaro A, Cirillo I, et al. Bacillus clausii effects in children with allergic rhinitis. Allergy. 2005a;60:702–3.
    1. Ciprandi G, Vizzaccaro A, Cirillo I, et al. Bacillus clausii exerts immuno-modulatory activity in allergic subjects: a pilot study. Eur Ann Allergy Clin Immunol. 2005b;37:129–33.
    1. Ciprandi G, Tosca MA, Fasce L. Allergic children have more numerous and severe respiratory infections than non-allergic children. Ped Allergy Immunol. 2006;17:389–91.
    1. Duc LH, Hong HA, Barbosa TM, et al. Characterization of bacillus probiotics available for human use. Appl Env Microbiology. 2004;70:2161–71.
    1. Elson CO, Cong Y. Understanding Immune-microbial homeostasis in intestine. Immunol Res. 2002;26:87–94.
    1. Fiorini G, Cimminiello C, Chianese R. Bacillus subtilis selectively stimulates the synthesis of membrane bound and secreted IgA. Chemioterapia. 1985;4:310–12.
    1. Gruppo di studio di Immunologia della società Italiana di Pediatria. Le infezioni ricorrenti nel bambino: definizione ed approccio diagnostico. Riv Immunol Allergol Pediatrica. 1988;2:127–34.
    1. Hatakka K, Savilahti E, Ponka A. Effect of long term consumption of probiotic milk on infections in children attending day care centers: double blind, randomised trial. BMJ. 2001;322:1–5.
    1. Holt PG, Sly PD, Bjorksten B. Atopic versus infectious diseases in childhood: a question of balance? Pediatr Allergy Immunol. 1997;8:53–8.
    1. Isolauri E, Sutas Y, Kankaanpaa P, et al. Probiotics: effects on immunity. Am J Clin Nutr. 2001;73:444s–450s.
    1. Kaur IP, Chopra K, Saini A. Probiotics: potential pharmaceutical applications. Eur J Pharm Sci. 2002;15:1–9.
    1. Sporn MB, Roberts AB. Transforming growth factor-beta recent progress and new challenges. J Cell Biol. 1992;119:1017–21.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere